Inventor · disambiguated record
Meibi Dai
Also filed as: DAI MEIBI
12 granted patents·3 pending applications·12 citations·filing 2014–2023
83Inventor score
Files withCGENETECH SUZHOU CHINA CO LTD2GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD2MEDSHINE DISCOVERY INC2NOVAONCO JS THERAPEUTICS CO LTD2WUXI LIFE FOUNTAIN BIOTECH CO LTD2
Top patents by PatentIndex Score
15 records- 0187US10519133B2Vinyl compounds as FGFR and VEGFR inhibitorsMEDSHINE DISCOVERY INC·Filed 2016·Granted Dec 31, 2019·4 cites·16 claims
- 0281US12378241B2Pyridine derivative as FGFR and VEGFR dual inhibitorsCGENETECH SUZHOU CHINA CO LTD·Filed 2020·Granted Aug 5, 2025·1 cites·20 claims
- 0377US9834563B2Antidiabetic substituted heteroaryl compoundsMERCK SHARP & DOHME·Filed 2014·Granted Dec 5, 2017·4 cites·13 claims
- 0473US12297197B2Pyrazolopyridine compound as RET inhibitor and application thereofGUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO LTD BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY·Filed 2020·Granted May 13, 2025·1 cites·19 claims
- 0573US11008292B2FGFR4 inhibitor and preparation method and use thereofGUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD·Filed 2017·Granted May 18, 2021·1 cites·15 claims
- 0665US11161817B2Quinoline derivative and use thereof as tyrosine kinase inhibitorCHONGQING PHARMACEUTICAL INDUSTRIAL RES INSTITUTE CO LTD·Filed 2018·Granted Nov 2, 2021·1 cites·9 claims
- 0763US2025295642A1Fluoroquinoxalinone derivative for selectively inhibiting parp1MEDSHINE DISCOVERY INC·Filed 2023·Application pending·0 cites
- 0859US11919898B2Crystal form of azaindole derivative and use thereofWUXI LIFE FOUNTAIN BIOTECH CO LTD·Filed 2021·Granted Mar 5, 2024·0 cites·18 claims
- 0957US2024409534A1Crystal form of methylpyrazole-substituted pyridoimidazole compound and preparation method thereforCGENETECH SUZHOU CHINA CO LTD·Filed 2022·Application pending·0 cites
- 1052US2023106064A1Crystalline form of fluvatinib or fluvatinib methanesulfonate and preparation method thereforCHONGQING PHARMACEUTICAL RES INSTITUTE CO LTD·Filed 2021·Application pending·0 cites
- 1151US11440903B2Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereofGUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD·Filed 2018·Granted Sep 13, 2022·0 cites·26 claims
- 1246US11078194B2Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method thereforHARBIN ZHENBAO PHARMACEUTICAL CO LTD·Filed 2018·Granted Aug 3, 2021·0 cites·10 claims
- 1345US12312347B2Azaindole derivative and use thereof as FGFR and C-Met inhibitorWUXI LIFE FOUNTAIN BIOTECH CO LTD·Filed 2019·Granted May 27, 2025·0 cites·18 claims
- 1441US12509440B2Fluorovinylbenzamide compound as PD-L1 immunomodulatorNOVAONCO JS THERAPEUTICS CO LTD·Filed 2020·Granted Dec 30, 2025·0 cites·7 claims
- 1540US12152013B2Vinylpyridine carboxamide compound as PD-L1 immunomodulatorNOVAONCO JS THERAPEUTICS CO LTD·Filed 2020·Granted Nov 26, 2024·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Meibi Dai files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →